How do research and development costs impact pharmaceutical drug pricing?
November 15, 2024
Research and development (R&D) costs significantly influence pharmaceutical drug pricing, which is a contentious issue due to its implications for innovation, access, and affordability. The estimates for bringing a new drug to market range considerably, suggesting no consensus on the precise costs involved. Estimates vary from $161 million to over $2.8 billion due to differences in methodologies, therapeutic categories, and the inclusion of failed attempts and postmarketing studies (1, 2, 7). The high costs associated with R&D are often cited by the pharmaceutical industry to justify high drug prices, which serve as a mechanism to recuperate investments and fund future innovation (5, 6, 9). Pharmaceutical pricing strategies such as value-based pricing, tiered pricing, and reference pricing are employed to balance patient access with ongoing innovation (17, 29). However, regulatory approaches, like price controls, can adversely impact R&D by reducing anticipated revenues, thereby diminishing investment incentives and potentially leading to fewer drug innovations (3, 4, 12). The elasticity of R&D to drug pricing changes suggests that any price control measures could significantly diminish R&D activities and consequently, the availability of new drugs (3, 12, 46).
Empirical evidence links high drug prices not just to R&D recovery but also to market dynamics, such as competition levels and patent protections (3, 30). Differential and dynamic pricing, tailored to market characteristics and disease specificity, is proposed as a way to optimize both access and innovation, balancing pricing pressures with the sustaining of pharmaceutical R&D investment (16, 17). Transparency in drug cost and pricing remains crucial for evaluating the cost-effectiveness and societal impacts of pharmaceuticals (6, 41).
In conclusion, while R&D costs are integral to drug pricing, they are modulated by regulatory policies and market dynamics. Balancing these factors to sustain innovation while ensuring accessibility and affordability is pivotal, calling for nuanced and transparent pricing strategies and policy frameworks.
References
1. Schlander, Michael, et al. "How much does it cost to research and develop a new drug? A systematic review and assessment." Pharmacoeconomics 39 (2021): 1243-1269.
2. Sertkaya, Aylin, et al. "Costs of drug development and research and development intensity in the US, 2000-2018." JAMA Network Open 7.6 (2024): e2415445-e2415445.
3. Giaccotto, Carmelo, Rexford E. Santerre, and John A. Vernon. "Drug prices and research and development investment behavior in the pharmaceutical industry." The Journal of Law and Economics 48.1 (2005): 195-214.
4. Vernon, John A. "Examining the link between price regulation and pharmaceutical R&D investment." Health Economics 14.1 (2005): 1-16.
5. Vogel, Ronald J. "Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union." Clinical therapeutics 26.8 (2004): 1327-1340.
6. Hay, Joel W., et al. "Good research practices for measuring drug costs in cost-effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report—Part I." Value in Health 13.1 (2010): 3-7.
7. Rennane, Stephanie, Lawrence Baker, and Andrew Mulcahy. "Estimating the cost of industry investment in drug research and development: a review of methods and results." INQUIRY: The Journal of Health Care Organization, Provision, and Financing 58 (2021): 00469580211059731.
8. DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. "The price of innovation: new estimates of drug development costs." Journal of Health Economics 22.2 (2003): 151-185.
9. Moreno, Santiago G., and David Epstein. "The price of innovation—the role of drug pricing in financing pharmaceutical innovation. A conceptual framework." Journal of Market Access & Health Policy 7.1 (2019): 1583536.
10. Danzon, Patricia M., and Adrian Towse. "Differential pricing for pharmaceuticals: reconciling access, R&D and patents." International Journal of Health Care Finance and Economics 3 (2003): 183-205.
11. Camejo, Rodrigo Refoios, Clare McGrath, and Ron Herings. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness." Health Policy 100.1 (2011): 18-24.
12. Abbott, Thomas A., and John A. Vernon. "The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions." Managerial and Decision Economics 28.4-5 (2007): 293-306.
13. Winegarden, Wayne. "The economics of pharmaceutical pricing." San Francisco, CA: Pacific Research Institute (2014).
14. Scherer, Frederic M. "Pricing, profits, and technological progress in the pharmaceutical industry." Journal of Economic Perspectives 7.3 (1993): 97-115.
15. Wouters, Olivier J., Martin McKee, and Jeroen Luyten. "Estimated research and development investment needed to bring a new medicine to market, 2009-2018." JAMA 323.9 (2020): 844-853.
16. Danzon, Patricia M. "Differential pricing of pharmaceuticals: theory, evidence and emerging issues." PharmacoEconomics 36.12 (2018): 1395-1405.
17. Schoonveld, Ed. The price of global health: drug pricing strategies to balance patient access and the funding of innovation. Routledge, 2016.
18. Vagelos, P. Roy. "Are prescription drug prices high?" Science 252.5009 (1991): 1080-1084.
19. Grabowski, Henry. "Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures." PharmacoEconomics 22 (2004): 15-24.
20. DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. "Innovation in the pharmaceutical industry: new estimates of R&D costs." Journal of Health Economics 47 (2016): 20-33.
21. McGuire, Alistair, Maria Raikou, and Panos Kanavos. "Pricing pharmaceuticals: Value based pricing in what sense." Eurohealth 14.2 (2008): 3-5.
22. Civan, Abdulkadir, and Michael T. Maloney. "The determinants of pharmaceutical research and development investments." The BE Journal of Economic Analysis & Policy 5.1 (2006).
23. Parker-Lue, Sara, Michael Santoro, and Greg Koski. "The ethics and economics of pharmaceutical pricing." Annual Review of Pharmacology and Toxicology 55.1 (2015): 191-206.
24. Galizzi, Matteo Maria, Simone Ghislandi, and Marisa Miraldo. "Effects of reference pricing in pharmaceutical markets: a review." PharmacoEconomics 29 (2011): 17-33.
25. Garrison Jr, Louis P., et al. "Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II." Value in Health 13.1 (2010): 8-13.
26. Manders, Evert A., et al. "Drug pricing models, no one-size-fits-all approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape." The European Journal of Health Economics (2024): 1-14.
27. Barton, John H., and Ezekiel J. Emanuel. "The patents-based pharmaceutical development process: rationale, problems, and potential reforms." JAMA 294.16 (2005): 2075-2082.
28. Babar, Zaheer-Ud-Din, and Muhammad Atif. "Differential pricing of pharmaceuticals: a bibliometric review of the literature." Journal of Pharmaceutical Health Services Research 5.3 (2014): 149-156.
29. Lu, Z. John, and William S. Comanor. "Strategic pricing of new pharmaceuticals." Review of Economics and Statistics 80.1 (1998): 108-118.
30. Gregson, Nigel, et al. "Pricing medicines: theory and practice, challenges and opportunities." Nature Reviews Drug Discovery 4.2 (2005): 121-130.
31. Danzon, Patricia M. "Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU." International Journal of the Economics of Business 4.3 (1997): 301-322.
32. Xing-Cai, L, et al. "Effect of cetane number improver on heat release rate and emissions of high speed diesel engine fueled with ethanol–diesel blend fuel." Fuel 83.14-15 (2004): 2013-2020.
33. Golec, Joseph, and John A. Vernon. "Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms." PharmacoEconomics 28 (2010): 615-628.
34. Rao, Anita. "Strategic research and development investment decisions in the pharmaceutical industry." Marketing Science 39.3 (2020): 564-586.
35. Lee, Kah Seng, et al. "Factors impacting pharmaceutical prices and affordability: narrative review." Pharmacy 9.1 (2020): 1.
36. Jarosławski, Szymon, et al. "Non-profit drug research and development at a crossroads." Pharmaceutical Research 35 (2018): 1-6.
37. Chorniy, Anna, et al. "Regulatory review time and pharmaceutical research and development." Health Economics 30.1 (2021): 113-128.
38. Serajuddin, Hamida K., and Abu T.M. Serajuddin. "Value of pharmaceuticals: ensuring the future of research and development." Journal of the American Pharmacists Association 46.4 (2006): 511-516.
39. Kang, So-Yeon, et al. "Comparative approaches to drug pricing." Annual Review of Public Health 41.1 (2020): 499-512.
40. Puig-Junoy, Jaume. "What is required to evaluate the impact of pharmaceutical reference pricing?" Applied Health Economics and Health Policy 4 (2005): 87-98.
41. Vogler, Sabine, et al. "How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries." Applied Health Economics and Health Policy 15 (2017): 307-321.
42. Gronde, Toon van der, Carin A. Uyl-de Groot, and Toine Pieters. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks." PLoS One 12.8 (2017): e0182613.
43. DiMasi, Joseph A., and Cherie Paquette. "The economics of follow-on drug research and development: trends in entry rates and the timing of development." PharmacoEconomics 22 (2004): 1-14.
44. Angelis, Aris, et al. "High drug prices are not justified by industry’s spending on research and development." BMJ 380 (2023).
45. Towse, Adrian. "Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?" British Journal of Clinical Pharmacology 70.3 (2010): 360-366.
46. Philipson, Tomas, and Troy Durie. "The evidence base on the impact of price controls on medical innovation." Becker Friedman Institute of Economics Working Paper 2021-108 (2021).
47. Grabowski, Henry, John Vernon, and Joseph A. DiMasi. "Returns on research and development for 1990s new drug introductions." PharmacoEconomics 20 (2002): 11-29.
48. Taylor, David. "The pharmaceutical industry and the future of drug development." (2015).
49. Incze, András, et al. "Assessing the consequences of external reference pricing for global access to medicines and innovation: economic analysis and policy implications." Frontiers in Pharmacology 13 (2022): 815029.
50. Halpenny, Genevieve M. "High drug prices hurt everyone." ACS Medicinal Chemistry Letters 7.6 (2016): 544-546.